Fundz
Following Scancell Holdings?

Get the free weekly contract digest

The latest new contracts, like Scancell Holdings’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma

Sep 17, 2024almost 2 years ago

Contract Type

partnership

BiotechnologyHealth CareTherapeutics

Description

PharmaJet has entered into a long-term partnership agreement with Scancell Holdings plc to use the PharmaJet Stratis® Intramuscular (IM) Needle-free System for the delivery of its advanced melanoma DNA vaccine. Under the agreement, Scancell will use Stratis for clinical development and commercialization, and PharmaJet will receive milestone payments and royalties on net sales.

Company Information

Company

Scancell Holdings

About

Scancell Holdings is a biotechnology company specializing in cancer immunotherapies. It develops innovative treatments based on its proprietary technologies. The company is listed on the London Stock Exchange. Scancell focuses on creating therapies to enhance the body's immune response to cancer.

Predictive Intelligence
Strategic

ML-powered predictions for Scancell Holdings's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.